Panacea Global Inc.

Panacea Global Inc.

November 07, 2013 10:00 ET

Panacea Global Announces Presentations on Its Cancer Diagnostic Technology at BIT's 3rd Annual World Congress of Molecular Medicine

TORONTO, ONTARIO--(Marketwired - Nov. 7, 2013) - Panacea Global, Inc. ("Panacea") (OTCBB:PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, today announced that Dr. Mahmood Moshiri, Panacea's President and CEO, will present the company's innovative cancer diagnostic technology at BIT Life Sciences' 3rd Annual World Congress of Molecular Medicine (MolMed-2013). The Congress will be held in Haikou, China from November 13-16, 2013.

Dr. Moshiri will give three presentations at MolMed-2013. The first, titled "Early Diagnosis of Cancer: HAAH-A Predictive Biomarker, A Serum Immunoassay and Personalized Medicine", will be presented at the Keynote Forum on November 13th. Dr. Moshiri will also give two presentations on HAAH as a serum biomarker for diagnosis of lung and colon cancers. These talks will be given at Cancer Biomarkers and Healthcare and Personalized Medicine sessions, which Dr. Moshiri will co-chair.

"Panacea is committed to the development of innovative and truly effective diagnostic tests for cancer detection," commented Dr. Moshiri. "HAAH is a highly sensitive and specific biomarker for colon cancer and early stage lung cancer. I'm very pleased to present at MolMed-2013, which is an important international event for advances in cancer research."

This year's MolMed-2013 also includes sessions on molecular diagnostics, molecular targets and cancer therapeutics, as well as a Nobel Laureate Forum that features Nobel Prize-winning scientists. For more information about BIT Life Sciences' 3rd Annual World Congress of Molecular Medicine, please visit

About BIT Life Sciences

BIT Life Sciences, a subsidiary of BIT Congress Inc., is dedicated to creating a global life science intelligence exchange by addressing professional needs for information and technology sharing while eliminating culture divergence in the bio-industries. BIT Life Sciences aims to be the world leader in intelligence exchange by integrating intelligence resources through well-organized events, courses, and talent searches. For more information about BIT Life Sciences, please visit

About Panacea Global

Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea's test is based on the detection of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients' blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (OTCBB:PANG) is available at

Forward-looking statements

Certain information contained in this document may include "forward-looking statements". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management's good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.

Contact Information